# EDGAR Filing Document

**Accession Number:** 0000862692
**File Stem:** 0001193125-26-248432
**Filing Date:** 2026-5
**Character Count:** 7556
**Document Hash:** 50fad41636b5a7433a0cc2e9fcdd66b3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-248432.hdr.sgml**: 20260529

**ACCESSION NUMBER**: 0001193125-26-248432

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260528

**FILED AS OF DATE**: 20260529

**DATE AS OF CHANGE**: 20260529

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** TAYMANS JILL M
- **CENTRAL INDEX KEY:** 0001261283

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40767
- **FILM NUMBER:** 261045100

**MAIL ADDRESS:**
- **STREET 1:** 3165 MCMULLEN BOOTH RD.
- **CITY:** CLEARWATER
- **STATE:** FL
- **ZIP:** 33761
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CRYO CELL INTERNATIONAL INC
- **CENTRAL INDEX KEY:** 0000862692
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 223023093
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1130

**BUSINESS ADDRESS:**
- **STREET 1:** 700 BROOKER CREEK BLVD
- **STREET 2:** SUITE 1800
- **CITY:** OLDSMAR
- **STATE:** FL
- **ZIP:** 34677
- **BUSINESS PHONE:** 813-749-2104

**MAIL ADDRESS:**
- **STREET 1:** 700 BROOKER CREEK BLVD
- **STREET 2:** SUITE 1800
- **CITY:** OLDSMAR
- **STATE:** FL
- **ZIP:** 34677

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>TAYMANS JILL M<br><sub>(Last) (First) (Middle)</sub><br>700 BROOKER CREEK BLVD.<br>SUITE 1800<br><sub>(Street)</sub><br>OLDSMAR, FL 34677<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-28 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_VP Finance, CFO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>CRYO CELL INTERNATIONAL INC [ CCEL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-28 |  | M |  | 7500 | A | $3.10 | 52896 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option | $8 |  |  |  |  |  |  | 2020-09-23<sup>(1)</sup> | 2027-09-23 | Common Stock | 7000 |  | 7000 | D |  |
| Stock Option | $4.62 |  |  |  |  |  |  | 2023-01-13 | 2028-01-13 | Common Stock | 20000 |  | 20000 | D |  |
| Stock Option | $5.88 |  |  |  |  |  |  | 2023-12-22<sup>(2)</sup> | 2028-12-22 | Common Stock | 10000 |  | 10000 | D |  |
| Stock Option | $7.35 |  |  |  |  |  |  | 2025-01-21<sup>(3)</sup> | 2030-01-21 | Common Stock | 10000 |  | 10000 | D |  |
| Stock Option | $3.54 |  |  |  |  |  |  | 2026-01-07<sup>(4)</sup> | 2031-01-07 | Common Stock | 10000 |  | 10000 | D |  |
| Stock Option | $3.54 |  |  |  |  |  |  | 2026-01-07<sup>(5)</sup> | 2031-01-07 | Common Stock | 20000 |  | 20000 | D |  |
| Stock Option | $3.10 | 2026-05-28 |  | M |  |  | 7500 | 2019-06-02 | 2026-06-02 | Common Stock | 7500 | $3.10 | 0 | D |  |

---

### Footnotes:

(1) Stock options vest 1/5 per year commencing on September 23, 2020.

(2) Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.

(3) Stock options vest 1/3 upon issuance, 1/3 on January 22, 2026 and 1/3 on January 22, 2027.

(4) Stock options vest 1/3 upon issuance, 1/3 on January 7, 2027 and 1/3 on January 7, 2028.

(5) The stock options were granted pursuant to the Cryo-Cell 2022 Stock Incentive Plan and an individual award agreement. The options are divided into three equal tranches, each subject to both time-based vesting and stock-price performance conditions. One tranche vests after the first anniversary of the grant date and upon the Company's common stock achieving an average closing price of at least $6 per share over 20 consecutive trading days. One tranche vests after the second anniversary and upon achieving an average closing price of at least $8 per share over 20 consecutive trading days. One tranche vests after the third anniversary and upon achieving an average closing price of at least $10 per share over 20 consecutive trading days, in each case subject to the reporting person's continued service to the Company.

**Signature:** /s/ Jill Taymans  
**Date:** 2026-05-29

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**